- Home
- HMST vs SGHT Comparison
HMST vs SGHT Comparison
Compare HMST & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- SGHT
- Stock Information
- Founded
- HMST 1921
- SGHT 2011
- Country
- HMST United States
- SGHT United States
- Employees
- HMST N/A
- SGHT N/A
- Industry
- HMST Major Banks
- SGHT Medical Specialities
- Sector
- HMST Finance
- SGHT Health Care
- Exchange
- HMST Nasdaq
- SGHT Nasdaq
- Market Cap
- HMST 287.6M
- SGHT 304.4M
- IPO Year
- HMST 2012
- SGHT 2021
- Fundamental
- Price
- HMST $11.93
- SGHT $4.02
- Analyst Decision
- HMST Buy
- SGHT Buy
- Analyst Count
- HMST 2
- SGHT 6
- Target Price
- HMST $13.25
- SGHT $6.80
- AVG Volume (30 Days)
- HMST 219.4K
- SGHT 283.3K
- Earning Date
- HMST 01-27-2025
- SGHT 11-07-2024
- Dividend Yield
- HMST 3.38%
- SGHT N/A
- EPS Growth
- HMST N/A
- SGHT N/A
- EPS
- HMST N/A
- SGHT N/A
- Revenue
- HMST $169,710,000.00
- SGHT $79,543,000.00
- Revenue This Year
- HMST N/A
- SGHT $2.18
- Revenue Next Year
- HMST $12.08
- SGHT $8.14
- P/E Ratio
- HMST N/A
- SGHT N/A
- Revenue Growth
- HMST N/A
- SGHT N/A
- 52 Week Low
- HMST $7.16
- SGHT $2.58
- 52 Week High
- HMST $16.10
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- HMST 50.12
- SGHT 39.37
- Support Level
- HMST $11.25
- SGHT $3.86
- Resistance Level
- HMST $12.31
- SGHT $4.11
- Average True Range (ATR)
- HMST 0.47
- SGHT 0.22
- MACD
- HMST 0.21
- SGHT 0.07
- Stochastic Oscillator
- HMST 78.77
- SGHT 40.66
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.